PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-25.60%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-60.64%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
1.26%
Positive EBIT growth while CSIQ is negative. John Neff might see a substantial edge in operational management.
-2402.01%
Negative operating income growth while CSIQ is at 1.80%. Joel Greenblatt would press for urgent turnaround measures.
-126.30%
Negative net income growth while CSIQ stands at 63.32%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-121.25%
Negative EPS growth while CSIQ is at 64.60%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-127.00%
Negative diluted EPS growth while CSIQ is at 64.29%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
10.75%
Slight or no buybacks while CSIQ is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
13.64%
Slight or no buyback while CSIQ is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-7700.65%
Negative OCF growth while CSIQ is at 100.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-934.80%
Negative FCF growth while CSIQ is at 100.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-27.10%
Negative 10Y revenue/share CAGR while CSIQ stands at 76.45%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-20.32%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
12.30%
3Y revenue/share CAGR at 50-75% of CSIQ's 18.78%. Martin Whitman would question if the firm lags behind competitor innovations.
-635.26%
Negative 10Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-23.78%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-16.38%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-106.42%
Negative 10Y net income/share CAGR while CSIQ is at 5221.49%. Joel Greenblatt sees a major red flag in long-term profit erosion.
88.32%
5Y net income/share CAGR 1.25-1.5x CSIQ's 67.94%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
99.12%
Below 50% of CSIQ's 908.06%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-99.63%
Negative equity/share CAGR over 10 years while CSIQ stands at 122.92%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-99.51%
Negative 5Y equity/share growth while CSIQ is at 82.48%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-99.06%
Negative 3Y equity/share growth while CSIQ is at 59.82%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.60%
Our AR growth while CSIQ is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
139.77%
Inventory growth well above CSIQ's 14.13%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-8.03%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-15.74%
We have a declining book value while CSIQ shows 5.60%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.27%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-14.37%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-6.94%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.